The departure of high-level, big pharma executives to tiny biotechs is steadily becoming a constant stream; the latest is Bill Hinshaw, former Executive Vice President of US Oncology at Novartis, who exits the company to head to Axcella Health, becoming its CEO.
Ook interessant voor je
Reageer